Korea Investment CORP lessened its holdings in Becton Dickinson and Co (NYSE:BDX) by 61.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,084 shares of the medical instruments supplier’s stock after selling 4,874 shares during the quarter. Korea Investment CORP’s holdings in Becton Dickinson and were worth $695,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. James Hambro & Partners boosted its stake in shares of Becton Dickinson and by 57.0% in the 4th quarter. James Hambro & Partners now owns 112,259 shares of the medical instruments supplier’s stock valued at $25,290,000 after purchasing an additional 40,750 shares during the last quarter. Nippon Life Global Investors Americas Inc. boosted its stake in shares of Becton Dickinson and by 10.4% in the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 38,970 shares of the medical instruments supplier’s stock valued at $8,781,000 after purchasing an additional 3,660 shares during the last quarter. Banque Pictet & Cie SA boosted its stake in shares of Becton Dickinson and by 25.0% in the 4th quarter. Banque Pictet & Cie SA now owns 38,524 shares of the medical instruments supplier’s stock valued at $8,680,000 after purchasing an additional 7,700 shares during the last quarter. Gofen & Glossberg LLC IL raised its position in shares of Becton Dickinson and by 5.5% in the 4th quarter. Gofen & Glossberg LLC IL now owns 43,228 shares of the medical instruments supplier’s stock valued at $9,740,000 after acquiring an additional 2,261 shares during the period. Finally, Granite Investment Advisors LLC raised its position in shares of Becton Dickinson and by 81.9% in the 4th quarter. Granite Investment Advisors LLC now owns 31,769 shares of the medical instruments supplier’s stock valued at $7,158,000 after acquiring an additional 14,300 shares during the period. 85.46% of the stock is currently owned by institutional investors.

Shares of BDX stock opened at $253.92 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97. The company has a market cap of $68.32 billion, a price-to-earnings ratio of 23.06, a P/E/G ratio of 1.76 and a beta of 1.21. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the consensus estimate of $2.58 by $0.12. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period last year, the company posted $2.48 EPS. On average, analysts forecast that Becton Dickinson and Co will post 12.1 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 8th will be issued a dividend of $0.77 per share. The ex-dividend date is Thursday, March 7th. This represents a $3.08 annualized dividend and a yield of 1.21%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.

A number of analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Becton Dickinson and in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 price target on the stock. TheStreet upgraded shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Zacks Investment Research downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Wednesday, February 6th. Piper Jaffray Companies increased their price target on shares of Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research report on Tuesday, February 5th. Finally, Deutsche Bank assumed coverage on shares of Becton Dickinson and in a research report on Thursday, December 6th. They issued a “buy” rating and a $280.00 price target on the stock. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $253.55.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the sale, the chief executive officer now directly owns 227,250 shares in the company, valued at approximately $56,903,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vincent A. Forlenza sold 3,123 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $255.03, for a total transaction of $796,458.69. Following the sale, the chief executive officer now owns 215,372 shares in the company, valued at $54,926,321.16. The disclosure for this sale can be found here. Insiders have sold a total of 19,271 shares of company stock worth $4,862,179 over the last 90 days. Corporate insiders own 0.12% of the company’s stock.

WARNING: This article was published by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.mareainformativa.com/news/2019/03/17/korea-investment-corp-sells-4874-shares-of-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: How to trade on quiet period expirations

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.